Advent Therapeutics, Inc.

Ben Franklin provides support for our therapy for neonatal Bronchopulmonary Dysplasia, a serious disorder afflicting premature infants, to launch in 14 months

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Lumberville, Bucks County, Pennsylvania, US
  • Currency USD
  • Founded May 2014
  • Employees 8
  • Incorporation Type C-corp
  • Website http://None - for competitive reasons

Company Summary

Advent was formed by industry execs with strong backgrounds in Neonatal / Pediatric & Orphan Drug therapies. We have been supported through three rounds of funding by Ben Franklin Tech Partners and are now positioned for US FDA approval of our lead product in mid-2018. Our proprietary, optimized Vitamin A Parenteral can significantly reduce the incidence of neonatal BPD, a serious, costly respiratory disorder afflicting at-risk premature infants

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free